Does Drugs Competing For Active Tubular Secretion Interact with Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen?
Drugs Competing For Active Tubular Secretion and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen have a moderate drug interaction according to U.S. FDA drug labeling data. Coadministration may increase concentrations of FTC and tenofovir by competing for renal tubular secretion. The mechanism involves ftc and tenofovir are excreted via active tubular secretion in kidneys. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Drugs Competing For Active Tubular Secretion and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen occurs because ftc and tenofovir are excreted via active tubular secretion in kidneys. Clinically, this means coadministration may increase concentrations of ftc and tenofovir by competing for renal tubular secretion. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Drugs Competing For Active Tubular Secretion and your doctor is considering prescribing Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider